Journal article
Prevention of cisplatin-induced ototoxicity in children and adolescents with cancer: a clinical practice guideline
DR Freyer, PR Brock, KW Chang, LL Dupuis, S Epelman, K Knight, D Mills, R Phillips, E Potter, D Risby, P Simpkin, M Sullivan, S Cabral, PD Robinson, L Sung
Lancet Child and Adolescent Health | Published : 2020
Abstract
Despite ototoxicity being a prevalent consequence of cisplatin chemotherapy, little guidance exists on interventions to prevent this permanent and progressive adverse event. To develop a clinical practice guideline for the prevention of cisplatin-induced ototoxicity in children and adolescents with cancer, we convened an international, multidisciplinary panel of experts and patient advocates to update a systematic review of randomised trials for the prevention of cisplatin-induced ototoxicity. The systematic review identified 27 eligible adult and paediatric trials that evaluated amifostine, sodium diethyldithiocarbamate or disulfiram, systemic sodium thiosulfate, intratympanic therapies, an..
View full abstractGrants
Awarded by National Cancer Institute
Funding Acknowledgements
The Pediatric Oncology Group of Ontario provided funding but did not influence the content of this manuscript or the decision to submit for publication. LS is supported by a Canada Research Chair in Pediatric Oncology Supportive Care.